<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067753</url>
  </required_header>
  <id_info>
    <org_study_id>ZJCH-2016-HN02</org_study_id>
    <nct_id>NCT03067753</nct_id>
  </id_info>
  <brief_title>Monosialoganglioside Ganglioside in Cerebral Radiation Necrosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monosialoganglioside Ganglioside in Cerebral Radiation Necrosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective phase II trial was conducted to test the efficacy of monosialoganglioside
      ganglioside for the treatment of cerebral radiation necrosis
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>From the first day of treatment, to 3 months after treatment</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST) were used.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Cerebral Radiation Necrosis</condition>
  <arm_group>
    <arm_group_label>Pulsed steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monosialoganglioside ganglioside</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monosialoganglioside Ganglioside</intervention_name>
    <description>Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.</description>
    <arm_group_label>Monosialoganglioside ganglioside</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone (Steroid Hormone)</intervention_name>
    <description>Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.</description>
    <arm_group_label>Pulsed steroid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <arm_group_label>Pulsed steroid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergone only one course of definitive radiotherapy for histologically confirmed
             nasopharyngeal carcinoma years before;

          -  At least two consecutive MRI study supporting the diagnosis of cerebral radiation
             necrosis(CRN) with an interval of 3-4 months, with the second MRI showing progressive
             disease compared with the first MRI;

          -  Progressive neurologic symptoms or signs;

          -  Mini-mental status examination(MMSE) score must be ≤27;

          -  Karnofsky performance status≥70 ;

          -  Supposed to live more than 6 months.

        Exclusion Criteria:

          -  After the second course of radiotherapy for recurrent nasopharyngeal carcinoma;

          -  Local or regional relapse,or with distant metastasis;

          -  Cerebrovascular disease;

          -  Second primary malignancy;

          -  Diabetes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xiaozhong Chen</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaozhong Chen, MD</last_name>
      <phone>+86-571-88128202</phone>
      <email>cxzfyun@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>February 24, 2017</last_update_submitted>
  <last_update_submitted_qc>February 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

